Selected research
Industry Growth & Trends
Global Glycopeptide Antibiotics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Glycopeptide Antibiotics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Glycopeptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Glycopeptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Glycopeptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Glycopeptide Antibiotics market include Allergan, Alvogen, ANI Pharmaceuticals, Aurobindo Pharma, Hikma Pharmaceuticals plc, Lytix Biopharma, Theravance Biopharma, Eli Lilly and Company and Shenwei Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Glycopeptide Antibiotics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Glycopeptide Antibiotics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Glycopeptide Antibiotics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Glycopeptide Antibiotics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Glycopeptide Antibiotics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Glycopeptide Antibiotics Market by Company
Allergan
Alvogen
ANI Pharmaceuticals
Aurobindo Pharma
Hikma Pharmaceuticals plc
Lytix Biopharma
Theravance Biopharma
Eli Lilly and Company
Shenwei Pharmaceutical
Zhejiang Hisun Pharmaceutical Co., Ltd.
Glycopeptide Antibiotics Segment by Type
Vancomycin
Teicoplanin
Bleomycin
Glycopeptide Antibiotics Segment by Application
Enterococcus Treatment
Staphylococcus Aureus Treatment
Glycopeptide Antibiotics Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glycopeptide Antibiotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glycopeptide Antibiotics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glycopeptide Antibiotics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Glycopeptide Antibiotics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Vancomycin
- Teicoplanin
- Bleomycin
Applications
- Enterococcus Treatment
- Staphylococcus Aureus Treatment
Companies covered
- Allergan
- Alvogen
- ANI Pharmaceuticals
- Aurobindo Pharma
- Hikma Pharmaceuticals plc
- Lytix Biopharma
- Theravance Biopharma
- Eli Lilly and Company
- Shenwei Pharmaceutical
- Zhejiang Hisun Pharmaceutical Co., Ltd.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Glycopeptide Antibiotics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Glycopeptide Antibiotics Market Size by Region (2021-2032)
- 1.4.1 Global Glycopeptide Antibiotics Market Size by Region (2021-2026)
- 1.4.2 Global Glycopeptide Antibiotics Market Size by Region (2027-2032)
- 1.5 Key Regions Glycopeptide Antibiotics Market Size (2021-2032)
- 1.5.1 North America Glycopeptide Antibiotics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Glycopeptide Antibiotics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Glycopeptide Antibiotics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Glycopeptide Antibiotics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Glycopeptide Antibiotics Market Size Growth Rate (2021-2032)
2 Glycopeptide Antibiotics Market by Type
- 2.1 Type Introduction
- 2.1.1 Vancomycin
- 2.1.2 Teicoplanin
- 2.1.3 Bleomycin
- 2.2 Global Glycopeptide Antibiotics Market Size by Type
- 2.2.1 Global Glycopeptide Antibiotics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Glycopeptide Antibiotics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Glycopeptide Antibiotics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Glycopeptide Antibiotics Market Size by Regions
- 2.3.1 North America Glycopeptide Antibiotics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Glycopeptide Antibiotics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Glycopeptide Antibiotics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Glycopeptide Antibiotics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Glycopeptide Antibiotics Market Size Breakdown by Type (2021-2026)
3 Glycopeptide Antibiotics Market by Application
- 3.1 Type Introduction
- 3.1.1 Enterococcus Treatment
- 3.1.2 Staphylococcus Aureus Treatment
- 3.2 Global Glycopeptide Antibiotics Market Size by Application
- 3.2.1 Global Glycopeptide Antibiotics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Glycopeptide Antibiotics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Glycopeptide Antibiotics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Glycopeptide Antibiotics Market Size by Regions
- 3.3.1 North America Glycopeptide Antibiotics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Glycopeptide Antibiotics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Glycopeptide Antibiotics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Glycopeptide Antibiotics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Glycopeptide Antibiotics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Glycopeptide Antibiotics Industry Trends
- 4.2 Glycopeptide Antibiotics Industry Drivers
- 4.3 Glycopeptide Antibiotics Industry Opportunities and Challenges
- 4.4 Glycopeptide Antibiotics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Glycopeptide Antibiotics Revenue (2021-2026)
- 5.2 Global Glycopeptide Antibiotics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Glycopeptide Antibiotics Key Company Headquarters & Area Served
- 5.4 Global Glycopeptide Antibiotics Company, Product Type & Application
- 5.5 Global Glycopeptide Antibiotics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Glycopeptide Antibiotics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Glycopeptide Antibiotics Players Market Share by Revenue in 2025
- 5.6.3 2025 Glycopeptide Antibiotics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Allergan
- 6.1.1 Allergan Company Information
- 6.1.2 Allergan Business Overview
- 6.1.3 Allergan Glycopeptide Antibiotics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Allergan Glycopeptide Antibiotics Product Portfolio
- 6.1.5 Allergan Recent Developments
- 6.2 Alvogen
- 6.2.1 Alvogen Company Information
- 6.2.2 Alvogen Business Overview
- 6.2.3 Alvogen Glycopeptide Antibiotics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Alvogen Glycopeptide Antibiotics Product Portfolio
- 6.2.5 Alvogen Recent Developments
- 6.3 ANI Pharmaceuticals
- 6.3.1 ANI Pharmaceuticals Company Information
- 6.3.2 ANI Pharmaceuticals Business Overview
- 6.3.3 ANI Pharmaceuticals Glycopeptide Antibiotics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 ANI Pharmaceuticals Glycopeptide Antibiotics Product Portfolio
- 6.3.5 ANI Pharmaceuticals Recent Developments
- 6.4 Aurobindo Pharma
- 6.4.1 Aurobindo Pharma Company Information
- 6.4.2 Aurobindo Pharma Business Overview
- 6.4.3 Aurobindo Pharma Glycopeptide Antibiotics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Aurobindo Pharma Glycopeptide Antibiotics Product Portfolio
- 6.4.5 Aurobindo Pharma Recent Developments
- 6.5 Hikma Pharmaceuticals plc
- 6.5.1 Hikma Pharmaceuticals plc Company Information
- 6.5.2 Hikma Pharmaceuticals plc Business Overview
- 6.5.3 Hikma Pharmaceuticals plc Glycopeptide Antibiotics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Hikma Pharmaceuticals plc Glycopeptide Antibiotics Product Portfolio
- 6.5.5 Hikma Pharmaceuticals plc Recent Developments
- 6.6 Lytix Biopharma
- 6.6.1 Lytix Biopharma Company Information
- 6.6.2 Lytix Biopharma Business Overview
- 6.6.3 Lytix Biopharma Glycopeptide Antibiotics Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Lytix Biopharma Glycopeptide Antibiotics Product Portfolio
- 6.6.5 Lytix Biopharma Recent Developments
- 6.7 Theravance Biopharma
- 6.7.1 Theravance Biopharma Company Information
- 6.7.2 Theravance Biopharma Business Overview
- 6.7.3 Theravance Biopharma Glycopeptide Antibiotics Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Theravance Biopharma Glycopeptide Antibiotics Product Portfolio
- 6.7.5 Theravance Biopharma Recent Developments
- 6.8 Eli Lilly and Company
- 6.8.1 Eli Lilly and Company Company Information
- 6.8.2 Eli Lilly and Company Business Overview
- 6.8.3 Eli Lilly and Company Glycopeptide Antibiotics Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Eli Lilly and Company Glycopeptide Antibiotics Product Portfolio
- 6.8.5 Eli Lilly and Company Recent Developments
- 6.9 Shenwei Pharmaceutical
- 6.9.1 Shenwei Pharmaceutical Company Information
- 6.9.2 Shenwei Pharmaceutical Business Overview
- 6.9.3 Shenwei Pharmaceutical Glycopeptide Antibiotics Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Shenwei Pharmaceutical Glycopeptide Antibiotics Product Portfolio
- 6.9.5 Shenwei Pharmaceutical Recent Developments
- 6.10 Zhejiang Hisun Pharmaceutical Co., Ltd.
- 6.10.1 Zhejiang Hisun Pharmaceutical Co., Ltd. Company Information
- 6.10.2 Zhejiang Hisun Pharmaceutical Co., Ltd. Business Overview
- 6.10.3 Zhejiang Hisun Pharmaceutical Co., Ltd. Glycopeptide Antibiotics Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Zhejiang Hisun Pharmaceutical Co., Ltd. Glycopeptide Antibiotics Product Portfolio
- 6.10.5 Zhejiang Hisun Pharmaceutical Co., Ltd. Recent Developments
7 North America
- 7.1 North America Glycopeptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Glycopeptide Antibiotics Market Size by Country (2021-2026)
- 7.3 North America Glycopeptide Antibiotics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Glycopeptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Glycopeptide Antibiotics Market Size by Country (2021-2026)
- 8.3 Europe Glycopeptide Antibiotics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Glycopeptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Glycopeptide Antibiotics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Glycopeptide Antibiotics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Glycopeptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Glycopeptide Antibiotics Market Size by Country (2021-2026)
- 10.3 South America Glycopeptide Antibiotics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Glycopeptide Antibiotics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Glycopeptide Antibiotics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Glycopeptide Antibiotics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst